Figure 1 Ischaemic endpoints

Slides:

Advertisements

Similar presentations

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Advertisements

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.

Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.

Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.

PRODIGY Objective Study Design Primary Composite Endpoint

Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.

RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.

¨ 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin.

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

M. Valgimigli, MD, PhD University of Ferrara, ITALY On behalf of the PRODIGY Investigators PROlonging Dual antiplatelet treatment after Grading stent-induced.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction †

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.

Randomized, non-inferiority trial of three limus agent- eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results:

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38.

Date of download: 9/16/2016 Copyright © The American College of Cardiology. All rights reserved. From: 5-Year Clinical Outcomes of the ARTS II (Arterial.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence and Correlates of Drug-Eluting Stent Thrombosis.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.

The SPRINT Research Group

Disclosures Speaker’s bureau: Research support: Consulting: Equity

Figure 1 A flow chart describing the systematic process followed for article selection. From: A systematic review of cost-effectiveness of percutaneous.

Figure 1 Patient flow chart.

Figure 2 Kaplan–Meier estimates of event-free survival (survival to the combined endpoint). From: Long-term outcomes of patients with acute myocardial.

Figure 1 Study flow chart.

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

Fig. 1 Flow chart of study selection

Figure 1 The flowchart depicts the total number of procedures in the Western Denmark Heart Registry (WDHR) and the exclusion of patients; NPR, National.

Figure 1 Prevalence of functional mitral regurgitation according to NYHA functional class (A; P

Figure 1 Incidence and total numbers of SCD in patients with depressed LV systolic function and in patients with preserved LV function. The incidence of.

Figure 1 Study flow chart

Incremental Value of the CRUSADE, ACUITY, and HAS‐BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients.

Preventing Thrombotic Complications in ACS: State of the Art

Oral Anticoagulation and Preventing Stent Thrombosis

Nat. Rev. Cardiol. doi: /nrcardio

Robert W. Yeh et al. JACC 2017;70:

Robert W. Yeh et al. JACC 2017;70:

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

NOACS: Emerging data in ACS/IHD

European Society of Cardiology 2003

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

3-Year Clinical Outcomes From the RESOLUTE US Study

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.

Figure 1 Periprocedural myonecrosis and myocardial infarction after left main coronary artery revascularization with ... Figure 1 Periprocedural myonecrosis.

Figure 1 Study flow diagram and definition of clinical response

Figure 1 Overall lag-cumulative exposure–response relationships between air temperature and myocardial infarction ... Figure 1 Overall lag-cumulative exposure–response.

John A. Bittl et al. JACC 2016;68:

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Overall (n=301) Acute/Subacute (n=149) Late (n=152) p Presentation

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care Marc Cohen, MD Mayo Clinic Proceedings

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Is Prasugrel Superior To Ticagrelor For The Treatment Of Patients With Acute Coronary Syndromes? Evidence From A 32,893-Patient Adjusted Indirect Comparison.

Seung-Yul Lee et al. JCIN 2018;j.jcin

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Forest plot of studies examining outcomes between patients taking proton pump inhibitor (PPIs) with clopidogrel and those taking only clopidogrel: (A)

Pamela E. Scott et al. JACC 2018;71:

Javier Escaned et al. JCIN 2018;11:

Presentation transcript:

Figure 1 Ischaemic endpoints Figure 1 Ischaemic endpoints. The overall population, the stable (stable coronary artery disease), and the unstable (acute coronary syndrome) subgroups are shown, with hazard ratios and 95% confidence intervals, for the primary endpoint of death for any cause, myocardial infarction (MI), or cerebrovascular accident (CVA), cardiovascular (CV) death or myocardial infarction, death for any cause and myocardial infarction (Death/MI), definite stent thrombosis (def ST) and definite/probable stent thrombosis (Def/prob ST) among patients randomly assigned to either the 6-month or the 24-month dual-antiplatelet therapy. From: Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial Eur Heart J. 2015;36(20):1242-1251. doi:10.1093/eurheartj/ehv038 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.

Figure 2 Cumulative incidence of ischaemic and bleeding events Figure 2 Cumulative incidence of ischaemic and bleeding events. Cumulative incidence curves are shown. (A) Death for any cause, myocardial infarction, or cerebrovascular accident in the stable and unstable group of the two treatment arms. (B) Bleeding according to the Bleeding Academic Research Consortium 2, 3, 5 criteria, in the stable and unstable group of the two treatment arms. From: Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial Eur Heart J. 2015;36(20):1242-1251. doi:10.1093/eurheartj/ehv038 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.

Figure 3 Bleeding endpoints Figure 3 Bleeding endpoints. The overall population, the stable (stable coronary artery disease), and the unstable (acute coronary syndrome) subgroups are shown, with hazard ratios and 95% confidence intervals, for the key safety endpoint of Bleeding Academic Research Consortium 2, 3, 5 bleeding, and further safety outcomes of Bleeding Academic Research Consortium 3 or 5, TIMI major and minor (TIMI MA/MIN), and GUSTO moderate and severe (GUSTO MOD/SEV) bleeding among patients randomly assigned to either the 6-month or the 24-month clopidogrel therapy. From: Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial Eur Heart J. 2015;36(20):1242-1251. doi:10.1093/eurheartj/ehv038 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.

Figure 4 Net adverse clinical event Figure 4 Net adverse clinical event. The overall population, the stable (stable coronary artery disease), and the unstable (acute coronary syndrome) subgroups are shown, with hazard ratios and 95% confidence intervals, for the net adverse clinical events of death for any cause, myocardial infarction, cardiovascular accident, or Bleeding Academic Research Consortium class 2, 3, 5 bleeding (NACE BARC 2–5), and for death for any cause, myocardial infarction, cardiovascular accident, or Bleeding Academic Research Consortium class 3, 5 bleeding (NACE BARC 3–5) among patients randomly assigned to either the 6-month or the 24-month clopidogrel therapy. From: Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial Eur Heart J. 2015;36(20):1242-1251. doi:10.1093/eurheartj/ehv038 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.

Figure 5 Cumulative incidence of net adverse clinical event Figure 5 Cumulative incidence of net adverse clinical event. Cumulative incidence curves are shown for the net adverse clinical events consisting of death for any cause, myocardial infarction, cerebrovascular accident, and Bleeding Academic Research Consortium class 2, 3, 5 bleeding. (A) Acute coronary syndrome subgroup and (B) stable coronary artery disease subgroup. From: Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial Eur Heart J. 2015;36(20):1242-1251. doi:10.1093/eurheartj/ehv038 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.